GlassScriptPhysician profile
Anju Vasudevan
NPI 1043203888
$64,536.36
in general payments reported to CMS, 2019-2025
100 companies · $11K in 2025
The $11K reported for 2025 was more than what 81% of Medical Oncology providers received nationally (typical 2025 total: $1,158).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $7,335 · 2020: $12K · 2021: $8,642 · 2022: $12K · 2023: $8,827 · 2024: $5,563 · 2025: $11K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K · Consulting Fee: $10K · Long Term Medical Supply Or Device Loan: $848 · Education: $735 · Honoraria: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,876.51 |
| Consulting Fee | $10,460.00 |
| Long Term Medical Supply Or Device Loan | $848.19 |
| Education | $734.96 |
| Honoraria | $200.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $11,030.39 | 2019-2025 | Calquence, Enhertu, Imfinzi |
| Seagen INC. | $4,814.72 | 2019-2025 | Adcetris, Tukysa, Tivdak |
| Beigene USA, INC. | $4,362.06 | 2020-2025 | Brukinsa |
| Incyte Corporation | $3,613.24 | 2019-2025 | Jakafi, Monjuvi, Zynyz |
| Novartis Pharmaceuticals Corporation | $3,610.03 | 2019-2025 | |
| Janssen Biotech, INC. | $2,821.27 | 2019-2025 | Darzalex, Erleada, Rybrevant |
| Glaxosmithkline, LLC. | $2,781.73 | 2020-2025 | Ojjaara, Zejula, Jemperli |
| Jazz Pharmaceuticals INC. | $2,624.58 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $2,295.92 | 2019-2025 | Opdivo, Opdualag, Krazati |
| Servier Pharmaceuticals LLC | $1,961.13 | 2021-2025 | |
| Celgene Corporation | $1,789.97 | 2019-2025 | Reblozyl, Pomalyst, Opdualag |
| G1 Therapeutics, INC. | $1,690.03 | 2021-2023 | Cosela |
| Merck Sharp & Dohme LLC | $1,398.43 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Blueprint Medicines Corporation | $1,286.08 | 2021-2022 | |
| Pfizer INC. | $1,188.28 | 2019-2025 |
Show all 97 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,080.25 | 2019-2024 | Lumakras, Vectibix, Xgeva |
| Astellas Pharma US INC | $975.14 | 2019-2025 | Padcev, Xtandi, Vyloy |
| Daiichi Sankyo INC. | $891.20 | 2019-2025 | Enhertu, Datroway |
| Janssen Scientific Affairs, LLC | $873.24 | 2020-2023 | Pipeline, Rybrevant |
| Eisai INC. | $847.66 | 2019-2025 | |
| Lilly USA, LLC | $722.38 | 2019-2025 | Jaypirca, Verzenio, Retevmo |
| Bayer Healthcare Pharmaceuticals INC. | $588.93 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $573.01 | 2019-2025 | Libtayo |
| Genentech USA, INC. | $535.03 | 2019-2025 | Venclexta, Polivy, Gazyva |
| Genzyme Corporation | $530.76 | 2019-2024 | |
| Pharmacosmos Therapeutics INC. | $480.62 | 2020-2025 | Monoferric, Cosela |
| Pharmacyclics LLC, An Abbvie Company | $474.44 | 2019-2023 | Imbruvica, Epkinly |
| Alexion Pharmaceuticals, INC. | $462.83 | 2019-2025 | Ultomiris, Soliris |
| Beigene, LTD. | $450.00 | 2020 | |
| Gilead Sciences, INC. | $448.03 | 2021-2025 | Trodelvy |
| Takeda Pharmaceuticals U.S.A., INC. | $437.27 | 2019-2025 | Fruzaqla, Alunbrig, Ninlaro |
| Puma Biotechnology, INC. | $382.16 | 2019-2025 | |
| Genmab U.S., INC. | $380.30 | 2023-2025 | Epkinly |
| Abbvie INC. | $271.43 | 2019-2025 | Venclexta, Creon |
| Emd Serono, INC. | $227.12 | 2022-2025 | Bavencio |
| Kite Pharma, INC. | $217.10 | 2020-2023 | Yescarta |
| Aveo Pharmaceuticals, INC. | $216.61 | 2021-2023 | Fotivda |
| Ipsen Biopharmaceuticals, INC | $209.20 | 2019-2024 | Onivyde, Somatuline Depot |
| Boehringer Ingelheim Pharmaceuticals, INC. | $209.04 | 2019-2025 | |
| Pharmaessentia USA Corporation | $204.08 | 2023-2025 | Besremi |
| Dova Pharmaceuticals | $200.81 | 2019-2021 | |
| Tesaro, INC. | $191.68 | 2019 | |
| Mirati Therapeutics, INC. | $186.82 | 2023-2024 | Krazati |
| Agios Pharmaceuticals, INC. | $183.68 | 2019-2025 | Pyrukynd |
| Foundation Medicine, INC. | $181.04 | 2019-2021 | |
| Karyopharm Therapeutics INC. | $168.34 | 2020-2024 | Xpovio |
| Rigel Pharmaceuticals, INC. | $164.77 | 2020-2023 | Rezlidhia, Tavalisse |
| Sobi, INC | $164.73 | 2022-2024 | |
| Array Biopharma INC | $162.70 | 2019-2025 | Mektovi, Braftovi, Lorbrena |
| Kyowa Kirin, INC. | $147.67 | 2019-2025 | Poteligeo |
| Stemline Therapeutics INC. | $142.16 | 2023-2025 | Orserdu |
| Heron Therapeutics, INC. | $137.90 | 2021-2023 | Cinvanti |
| Tg Therapeutics, INC. | $134.36 | 2021-2022 | |
| Lexicon Pharmaceuticals, INC. | $134.25 | 2019 | |
| Menarini Silicon Biosystems, INC. | $130.82 | 2025 | |
| Myriad Genetic Laboratories, INC. | $119.20 | 2022-2024 | Myrisk |
| Csl Behring | $117.86 | 2020-2024 | Afstyla, Idelvion |
| Novocure INC. | $116.77 | 2024-2025 | Optune Lua (Novottf-200t) |
| Morphosys, US INC. | $115.67 | 2021-2023 | Monjuvi |
| Beone Medicines USA, INC. | $104.50 | 2025 | Brukinsa, Tevimbra |
| Caris Mpi, INC. | $101.62 | 2025 | Mi Cancer Seek |
| Sun Pharmaceutical Industries INC. | $95.15 | 2020-2025 | |
| Epizyme, INC. | $93.69 | 2020-2022 | |
| Global Blood Therapeutics, INC. | $91.34 | 2020-2022 | |
| Fennec Pharmaceuticals, INC. | $77.39 | 2025 | Fyarro |
| Taiho Oncology, INC. | $71.49 | 2022-2025 | |
| Octapharma USA, INC. | $71.21 | 2022-2025 | Panzyga, Octagam Immune Globulin (Human) |
| Coherus Oncology, INC. | $61.66 | 2024-2025 | Loqtorzi |
| Tersera Therapeutics LLC | $61.32 | 2019-2023 | Zoladex |
| Apellis Pharmaceuticals, INC. | $60.97 | 2022-2024 | Empaveli |
| Legend Biotech USA INC. | $56.02 | 2025 | Carvykti |
| Deciphera Pharmaceuticals INC. | $55.95 | 2021-2025 | Romvimza, Qinlock |
| Adaptive Biotechnologies Corporation | $51.20 | 2022-2025 | Clonoseq |
| Dendreon Pharmaceuticals LLC | $46.98 | 2019-2025 | Provenge |
| Eusa Pharma (US) LLC | $45.39 | 2021-2022 | |
| Geron Corporation | $38.96 | 2024-2025 | Rytelo |
| Exelixis INC. | $36.82 | 2021-2023 | Cabometyx |
| Immunocore Limited | $36.18 | 2023 | Kimmtrak |
| Horizon Therapeutics Plc | $32.13 | 2019 | |
| Cti Biopharma Corp. | $31.68 | 2023 | Vonjo |
| Teva Pharmaceuticals USA, INC. | $29.95 | 2020 | |
| Emmaus Medical, INC. | $29.45 | 2019-2022 | |
| Ge Healthcare | $28.13 | 2021-2022 | |
| Corcept Therapeutics | $27.74 | 2025 | Korlym |
| Secura Bio, INC. | $25.41 | 2020-2023 | Copiktra |
| Recordati_rare_diseases_inc. | $22.96 | 2025 | Enjaymo |
| Springworks Therapeutics, INC. | $22.21 | 2025 | Ogsiveo |
| Janssen Pharmaceuticals, INC | $22.00 | 2024 | Rybrevant |
| Amneal Pharmaceuticals LLC | $20.10 | 2023 | Avastin |
| Medtronic, INC. | $19.58 | 2022 | |
| Adc Therapeutics America, INC. | $19.19 | 2023 | |
| Verastem, INC. | $19.11 | 2020 | |
| Verity Pharmaceuticals INC. | $15.27 | 2023 | Trelstar |
| Clovis Oncology, INC. | $15.25 | 2019 | |
| Alnylam Pharmaceuticals INC. | $14.95 | 2022 | |
| Acrotech Biopharma INC. | $13.80 | 2022 | |
| Helsinn Therapeutics (U.S.), INC. | $12.69 | 2019 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$2,064.87 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
$436,200.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anju Vasudevan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.